Site Logo
  • Contact Us
  • LinkedIn
  • About Stoke
    • Overview
    • Leadership
    • Founders
    • Corporate Responsibility
  • Scientific Platform
    • Overview
    • TANGO
    • Publications
  • Disease Areas
    • Overview
    • Dravet Syndrome
    • ADOA
    • SYNGAP1
    • Pipeline
  • Patients & Families
    • Overview
    • Clinical Studies
      • Expanded Access Policy
    • Educational Resources
  • Careers & Culture
    • Overview
    • Job Opportunities
    • Diversity, Inclusion & Belonging
  • Investors & News
    • Overview
    • Media Room
    • Press Releases
    • Events & Presentations
    • Financials & SEC Filings
    • Stock Information
    • Analyst Coverage
    • Governance
    • Settlement Information
  • About Stoke
    • Overview
    • Leadership
    • Founders
    • Corporate Responsibility
  • Scientific Platform
    • Overview
    • TANGO
    • Publications
  • Disease Areas
    • Overview
    • Dravet Syndrome
    • ADOA
    • SYNGAP1
    • Pipeline
  • Patients & Families
    • Overview
    • Clinical Studies
      • Expanded Access Policy
    • Educational Resources
  • Careers & Culture
    • Overview
    • Job Opportunities
    • Diversity, Inclusion & Belonging
  • Investors & News
    • Overview
    • Media Room
    • Press Releases
    • Events & Presentations
    • Financials & SEC Filings
    • Stock Information
    • Analyst Coverage
    • Governance
    • Settlement Information
  • Contact Us
  • Home
  • Scientific Platform
  • Publications
  • Dravet Syndrome Presentations

Small changes on the Vineland-3 are meaningful to caregivers of patients with Dravet syndrome

Topic: Dravet Syndrome Presentations

Small changes on the Vineland-3 are meaningful to caregivers of patients with Dravet syndrome

AES 2024

December 6, 2024

View Poster

Spectral EEG analysis demonstrates decreased slow-wave activity in patients with Dravet syndrome after treatment with zorevunersen (STK-001), an antisense oligonucleotide

AES 2024

December 6, 2024

View Poster

24-Month Analysis of BUTTERFLY A Prospective, Observational Study to Investigate Seizures and Comorbidities in Children and Adolescents with Dravet Syndrome

EEC 2024

September 10, 2024

View Poster
Prev Page
  • About Stoke
  • Scientific Platform
  • Disease Areas
  • Patients & Families
  • Careers & Culture
  • Investors & News
  • Contact Us
Stoke Logo

© 2026 Stoke Therapeutics, all rights reserved.

  • Privacy Statement
  • Terms of Use
  • Cookie Policy
  • Sitemap
  • LinkedIn